Praxis Precision Medicines is a biotechnology company developing experimental new medicine for patients and families impacted by mutations in the SCN2A gene. We are using an antisense oligonucleotide (ASO) to specifically target the SCN2A gene. In a second program, we are using a persistent sodium current blocker. We invite you to join us as we progress these exciting new potential treatments through clinical development.
Learn about the SCN2A gene, and signs and symptoms of SCN2A disorders. Plus, find support and other resources.Learn More
Clinical Research Studies
Interested in SCN2A research studies and other research opportunities?Learn More
Find out how to order no-cost genetic epilepsy testing panels and explore current clinical trial opportunities to share with families caring for children with SCN2A disorders.Learn More
Get the latest SCN2A community updates and find out how you can impact future SCN2A research.